## AAADV Workshop: CME Approved Sessions Worksheet (May 2-4, 2018)

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Session</th>
<th>Session Title</th>
<th>Approved Credits</th>
<th>Credits Claimed</th>
</tr>
</thead>
</table>
| **Wednesday **(May 2) | 9:30 a.m.-12:00 p.m. | Core Curriculum and In-Depth Discussion Groups I learners attend one | Core Curriculum -or- In-Depth Discussion Groups I (below)  
1: Challenges with New Clinical Trial Designs  
2: PROs and their Use in Cancer Drug Dev’t  
3: FDARA 2017 and the Future  
4: Impact of Precision Oncology on Health Disparities  
5: Access to Experimental Drugs Prior to FDA Approval | 2.5              |                  |
|               | 1:00 p.m.-3:00 p.m. | Plenary Session                               | Combinatorial Strategies in Immuno-oncology                                                           | 2.0              |                  |
|               | 3:30 p.m.-5:30 p.m. | Case Studies I learners attend one            | 1: Bavencio®, 3: Besponsa  
2: Kymriah™  
4: Vyxeos™ | 2.0              |                  |
| **Thursday **(May 3) | 8:30 a.m.-9:00 a.m. | Discussion Groups                             | Core Curriculum and Patient Advocate Breakfast Discussion Groups | n/a              |                  |
|               | 9:00 a.m.-10:00 a.m.| Keynote                                      | Keynote Address                                                                                       | 1.0              |                  |
|               | 10:30 a.m.-12:30 p.m.| In-Depth Discussion Groups II learners attend one | 1: Opp. and Chall. of Using Pragmatic Clinical Trials  
2: Int. Clinical Trials in Global Cancer Drug Dev’t  
3: Neoantigen-based Novel Cancer Therapies  
4: Drug Dev’t for Serious Hematologic Diseases  
5: Collaboration on Innovation in a "Crowded" Space | 2.0              |                  |
|               | 1:30 p.m.-3:30 p.m. | Case Studies II learners attend one           | 1: Zejula®, 4: Besponsa  
2: Keytruda®  
3: Bavencio®  
5: Kymriah™ | 2.0              |                  |
|               | 4:00 p.m.-6:00 p.m. | In-Depth Discussion Groups III learners attend one | 1: Augmenting Responses to Checkpoint Inhibitors  
2: Expanded Eligibility Criteria for Clinical Trials  
3: Circulating Free Tumor DNA  
4: Real World Data: Opportunities | 2.0              |                  |
| **Friday **(May 4) | 8:30 a.m.-9:00 a.m. | Discussion Groups                             | Core Curriculum and Patient Advocate Breakfast Discussion Groups | n/a              |                  |
|               | 9:00 a.m.-11:00 a.m. | Case Studies III learners attend one          | 1: Vyxeos™  
3: Keytruda®  
2: Zejula®  
4: Bavencio® | 2.0              |                  |
|               | 11:30 a.m.-1:30 p.m.| Case Studies IV learners attend one           | 1: Besponsa  
3: Vyxeos™  
2: Kymriah™  
4: Zejula® | 2.0              |                  |
|               |                     |                                              |                                                                                                        | 4.0              |                  |
|               |                     |                                              |                                                                                                        | 17.5             |                  |